A potentially revolutionary shift in access to weight-loss medications is on the horizon, with new analysis suggesting that drugs like Wegovy and Ozempic could be manufactured for as little as $3 per monthly dose. This development could dramatically expand treatment options for the more than one billion people worldwide living with obesity, particularly in lower-income nations where current prices pose a significant barrier to care. The findings, published as a pre-print study, highlight the potential for increased affordability as patents on semaglutide, the active ingredient in these medications, commence to expire.
The World Health Organization (WHO) designated semaglutide as an essential medicine in September 2023, recognizing its potential to address a growing global health crisis. However, the organization similarly cautioned that high costs were limiting access to the drug, particularly in regions where obesity rates are rapidly increasing alongside shifts towards Westernized diets and more sedentary lifestyles. This new research offers a pathway to overcoming that hurdle, potentially making a vital treatment accessible to millions who currently cannot afford it.
Researchers, led by Dr. Andrew Hill of Liverpool University’s pharmacology department, estimate that mass production of injectable semaglutide could reach a cost of $3 per dose, while a pill formulation could be produced for around $16 a month. These estimates are based on shipment records of key ingredients from 2024 and 2025, utilizing a methodology previously used to accurately predict the prices of generic medications for conditions like HIV, hepatitis C, and certain cancers. “These low prices open the door to worldwide access to an essential medicine,” Dr. Hill stated.
Patent Expiration and Generic Competition
A key factor driving down potential costs is the impending expiration of core patents on semaglutide. The research indicates that patents are set to expire in 10 countries this year, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, as of March 21st. This expiration will pave the way for generic manufacturers to enter the market, increasing competition and driving down prices. The researchers identified an additional 150 countries where patents have not been filed, including most of Africa, representing a significant opportunity for affordable access. These 160 countries are home to 69% of people with type 2 diabetes and 84% of those living with obesity, according to the study.
The success of this model has been demonstrated with other life-saving medications. Professor François Venter from Witwatersrand University in Johannesburg noted, “Drugs to treat HIV, TB, malaria and hepatitis are available in low- and middle-income countries for prices close to the cost of production, saving millions of lives while allowing generic companies to create sufficient profit to ensure sustainable supply. People can repeat this medical success story for semaglutide.”
Challenges and Considerations for Implementation
While the prospect of affordable semaglutide is encouraging, researchers emphasize that lower prices alone will not solve the obesity epidemic. They caution that addressing the underlying structural drivers of obesity – including food insecurity, poverty, urbanization, and the prevalence of highly processed foods – is crucial. Coordinated policies and procurement planning will be essential to realize the full benefits of increased affordability.
Dr. Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, highlighted the potential impact on low- and middle-income countries (LMICs). “This could be very significant for South Africa and many African countries and LMICs at large where cost has been one of the main barriers to access,” she said. Analysis suggests that approximately 27% of adults globally meet the criteria for medications like semaglutide, with the majority of those individuals residing in LMICs where access is currently limited.
The Broader Health Impact of Obesity
Obesity is a significant public health concern, linked to a range of serious health conditions, including heart disease, diabetes, stroke, and cancer. Globally, 3.7 million deaths are attributed to excess weight each year. The number of people living with diabetes has risen dramatically, from 200 million in 1990 to 830 million in 2022, with the most substantial increases occurring in low- and middle-income countries, according to the research.
Semaglutide was initially approved by US regulators in 2017. Currently, the cost is approximately $200 per month in the United States and £120 per month in the United Kingdom. However, patents in Britain, continental Europe, and the US will not expire for another five years, meaning these regions will likely not notice significant price reductions in the near term.
Médecins Sans Frontières conducted research in 2024 that also found diabetes drugs, including semaglutide, could be produced and sold at significantly lower costs, reinforcing the findings of this latest analysis.
The potential for widespread access to affordable semaglutide represents a major step forward in the fight against obesity, but successful implementation will require a multifaceted approach that addresses both cost and the underlying factors driving the global obesity epidemic. The coming months will be critical as countries prepare for patent expirations and explore strategies to ensure equitable access to this potentially life-changing medication.
This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential impact of more affordable weight-loss medications? Share your comments below.
